THe beta-Blocker Heart Attack Trial: studies of platelets and factor VIII
Abstract:
Serial studies of platelets and factor VIII were performed in 16 patients enrolled in the Beta Blocker Heart Attack Trial. Eight patients received placebo, and eight were treated with propranolol, in doses ranging from 40 to 320 mg per day for periods of from 6 to 31 months. No differences in platelet-collagen affinity, factor VIII coagulant activity, factor VIII related antigen, or ristocetin cofactor activity were observed between treated and untreated patients. However, circulating platelet aggregates, which were initially increased in both groups, significantly declined in those receiving propranolol (p less than 0.05). This indicates that customarily used doses of propranolol affect platelet reactivity in vivo.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care


